Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Aloe vera is a natural supplement that has been shown to lower blood glucose levels and improve cholesterol profiles. Aloe ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

recommendations are presented for the safe use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the perioperative period. Noting that GLP-1 RAs have revolutionized the care of patients with ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Direct-to-consumer telehealth company Hims & Hers is defending its sale of compounded glucagon-like peptide agonists ... difficulty accessing name brand GLP-1 solutions and a resolution of ...

These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss drugs, known as GLP-1 agonists, might transform societies and save countries ...